Skip to main content

Vivo Capital Fund VIII, L.P.'s Form 4 filing

Terns Pharmaceuticals, Inc.TERN · filed Sep 8, 2022

Accession no.
0001213900-22-054888
Filed
Sep 8, 2022, 8:00 PM ET
Trade date
Sep 7, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $2.16M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Vivo Capital Fund VIII, L.P.CIK 000161878810% Owner
Vivo Capital VIII, LLCCIK 000161878910% Owner
Vivo Capital Surplus Fund VIII, L.P.CIK 000162804810% Owner
Vivo Opportunity, LLCCIK 000172897010% Owner
Vivo Opportunity Fund Holdings, L.P.CIK 000193021410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 7, 2022Common StockPPurchaseAcquired+600,000$3.60+$2,160,0003,581,592IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)